Midazolam

Evidence Level: L2

Predicted Indications: 1

Midazolam

Pharmacist Assessment Report

Midazolam: From Anxiety to Insomnia

One-Sentence Summary

Midazolam is a short-acting benzodiazepine (GABA-A modulator), originally used for anxiety and sedation. The TxGNN model predicts it may be effective for insomnia, supported by 2 registered clinical trials (neither tests midazolam for chronic insomnia) and 10 publications, including several older randomised hypnotic studies. This is closer to re-confirming a known hypnotic use than to a novel repurposing.

Quick Overview

Item	Content
Original Indication	Anxiety (ARTG indication text is not available in the data compiled for this report)
Predicted New Indication	Insomnia
TxGNN Prediction Score	0.9974
Evidence Level	L2
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Midazolam is a benzodiazepine that enhances GABA-A receptor inhibition. This gives it potent sedative, hypnotic and anxiolytic effects, so a sleep indication is mechanistically consistent with its original use for anxiety.

Midazolam was studied orally as a hypnotic in the 1980s and 1990s. Studies included a dose-finding trial and a 14-day comparison with flurazepam in chronic insomniacs. It is also reported to be used as a hypnotic or sedative in some countries.

Its short half-life gives rapid onset but may limit sleep maintenance. Tolerance, dependence, next-day impairment and CYP3A4-mediated interactions remain concerns.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT02142595	Phase 4	Completed	111	Dexmedetomidine vs midazolam sedation with spinal anaesthesia, comparing postoperative sleep quality after transurethral prostatic resection. Relevant to sleep, but perioperative rather than chronic insomnia.
NCT00886314	N/A	Unknown	80	Clown doctors vs sedative premedication for preoperative anxiety in children. Not relevant to insomnia.

No ANZCTR identifiers were found in the data compiled for this report.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2121802	1990	RCT	J Clin Psychopharmacol	Double-blind multicentre study of sleep, performance and mood in chronic insomniacs over 14 days of flurazepam vs midazolam.
2229461	1990	RCT	J Clin Psychopharmacol	Executive summary of the same 14-day multicentre flurazepam vs midazolam study (no abstract available).
6120704	1981	RCT	Arzneimittel-Forschung	Oral midazolam 10–30 mg dose-finding in 75 hospitalised patients with mild to moderate insomnia secondary to other conditions.
6138072	1983	Clinical study (double-blind)	Br J Clin Pharmacol	Midazolam 15 mg vs Vesparax in 30 women with insomnia secondary to neuromuscular disease. Both were effective hypnotics; midazolam was better tolerated and caused no hangover.
2883820	1986	Review	Acta Psychiatr Scand Suppl	Indications for hypnotics and the need for benzodiazepines with different pharmacokinetic profiles.
17988972	2007	Review	Orv Hetil	General review of insomnia and cerebral hypoperfusion. Not midazolam-specific.
36615100	2022	Clinical study	J Clin Med	Lemborexant for insomnia and delirium prevention after endoscopic procedures. Benzodiazepines are discussed as a delirium risk.

The evidence is old and small-scale, and it was conducted before modern insomnia trial standards.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 10178Q	Sponsor: Pfizer Australia Pty Ltd	Injection 5 mg (as hydrochloride) in 1 mL	Not specified in the data compiled

The only Australian listing is an injectable. The oral hypnotic studies above used an oral formulation, so route compatibility has not been established.

Safety Considerations

Product Information warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.

Disease-level cautions (from knowledge base associations, not label text): chronic obstructive pulmonary disease, cirrhosis of the liver, angle-closure glaucoma and chronic kidney disease or end-stage renal failure.
Drug Interactions: 100 interactions were recorded. The main moderate-level examples are:
- Opioid and sedative combinations: morphine, dronabinol and nabilone.
- Possible metabolic interactions: clarithromycin, miconazole, clotrimazole, aprepitant, cimetidine, ranitidine, omeprazole and bupropion.
- Other moderate interactions: metoclopramide, eluxadoline, teduglutide and glycerol phenylbutyrate.
- Minor interactions include dexamethasone, betamethasone, magnesium oxide, aluminium hydroxide and calcium carbonate.
General concerns noted in the evidence review: tolerance, dependence, next-day impairment and CYP3A4 interactions.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanism is plausible, and older randomised studies suggest oral midazolam works as a hypnotic. However, the evidence is dated and the registered trials do not address chronic insomnia. The only ARTG listing is an injectable, and safety labelling data are missing. Current evidence supports this as a research question, not a clinical recommendation.

To proceed, the following is needed:

Product Information warnings and contraindications for Australia.
Mechanism of action data.
Confirmation of route and formulation (oral vs injectable) and ARTG indication wording.
Contemporary comparative trials against current insomnia treatments, with attention to dependence and next-day impairment.
A plan for managing CYP3A4 and CNS-depressant interactions.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.